Succinylcholine: Difference between revisions
No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
== Contraindications == | == Contraindications == | ||
{| style="width: 500px" border="1" cellpadding="1" cellspacing="1" | |||
|- | |||
| '''Contraindication<br/>''' | |||
| '''From-To''' | |||
|- | |||
| Known hyperK | |||
| current | |||
|- | |||
| Massive burns >10% BSA | |||
| >4dys-healed | |||
|- | |||
| Massive crush injuries | |||
| >4dys-healed | |||
|- | |||
| Denervation^ | |||
| >4dys-6mo | |||
|- | |||
| Neuromuscular dz^^ | |||
| indefinite | |||
|- | |||
| Intra-abdominal sepsis | |||
| >5dys-resolution | |||
|- | |||
| Increased ICP | |||
| may use w/ defacic dose | |||
|} | |||
^CVA (in particular those with residual deficits), spinal cord injury | ^CVA (in particular those with residual deficits), spinal cord injury | ||
| Line 23: | Line 42: | ||
2/06 DONALDSON (Adapted from Rosen) | 2/06 DONALDSON (Adapted from Rosen) | ||
Levitan, R. Annals of EM. Vol 45, Issue 2. Safety of succinylcholine in myasthenia gravis. | Levitan, R. Annals of EM. Vol 45, Issue 2. Safety of succinylcholine in myasthenia gravis.<br/> | ||
[[Category:Drugs]] | [[Category:Drugs]] <br/>[[Category:Airway/Resus]] | ||
[[Category:Airway/Resus]] | |||
Revision as of 04:53, 13 March 2011
Contraindications
| Contraindication |
From-To |
| Known hyperK | current |
| Massive burns >10% BSA | >4dys-healed |
| Massive crush injuries | >4dys-healed |
| Denervation^ | >4dys-6mo |
| Neuromuscular dz^^ | indefinite |
| Intra-abdominal sepsis | >5dys-resolution |
| Increased ICP | may use w/ defacic dose |
^CVA (in particular those with residual deficits), spinal cord injury
^^ALS, MS, skeletal muscle myopathies, cholinesterase def, h/o malignant hyperthermia
- No evidence to support contraindication in penetrating eye injuries
- N.B. Myasthenia Gravis- theoretically need more succ to induce vs nondepolarizing agents which have a prolonged effect.
- This is 2/2 to lack of post-synaptic receptors, i.e. succ cannot potentiate a reaction 2/2 too few receptors.
- Vs. it takes few "molecules" of roc/vec to block the few remaining functioning receptors.
- Overall, most practitioners tend to avoid succ in all patients with possible neuromuscular disease.
Source
2/06 DONALDSON (Adapted from Rosen)
Levitan, R. Annals of EM. Vol 45, Issue 2. Safety of succinylcholine in myasthenia gravis.